Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07461064

HIFU vs Observation for LSIL of Cervix: A Randomized Controlled Trial

The majority of low-grade pre-invasive lesions of cervix (low-grade squamous intraepithelial lesions, LSIL).will regress spontaneously over 2 years and immediate treatment may not be necessary. According to the Hong Kong College of Obstetricians and Gynaecologists (HKCOG), if a low-grade lesion is confirmed by colposcopy and biopsy, the patient can be observed and followed up with HPV testing or co-testing at 12 months, irrespective of age. This randomized controlled study is to determine whether high-intensity focused ultrasound (HIFU) treatment of low-grade pre-invasive lesions of cervix, can cause regression of these lesions in more patients within a specific time when compared to observation as a standard management according to HKCOG Guidelines. All eligible patients will be randomized in a 1:1 ratio into 2 groups: high-intensity focused ultrasound (HIFU) or Observation group. Background information of the patients such as age, parity, body mass index, smoking status and the presence of chronic medical disease will be collected. All patients with cervical HR-HPV status will be tested. Patients randomized into HIFU group will receive HIFU treatment within 2 weeks after randomization. Those randomized into Observation group will have no intervention. All patients will attend follow-up at 6 and 12 months after randomization, during which cervical smear for cytology (with cytopathologists blinded to the treatment group) and HR-HPV testing will be performed. The rate of cytological LSIL regression and HR-HPV clearance rates at 6 and 12 months in both groups will be analyzed. Patients will be referred back to colposcopy clinic for repeat colposcopy if needed according to HKCOG Guidelines. At the 12-month follow-up visit, if referral to repeat colposcopy is not needed, patients will be referred back to their primary care physicians, Department of Health Family Health Service, Family Planning Association or other primary care centres for follow-up cervical smears.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year–55 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Pre-menopausal women aged 18 years old or above.
  • Women had satisfactory colposcopy for abnormal cervical smear with positive HR-HPV test, with histologically confirmed diagnosis of cervix LSIL or CIN1.

Exclusion criteria

  • Women who are pregnant or breast feeding at the time of planned HIFU treatment.
  • Women without HR-HPV, or previously treated for CIN or cervical cancer.
  • Women not able to attend follow up.
  • Women with evidence of acute genital tract infection.
  • Women with significant autoimmune diseases, immunodeficiency diseases, severe cardiac, hepatic, renal, and coagulation dysfunctions.
  • Women not able to give consent.

Participants be considered withdrawn from study or excluded from analysis

  • Formally recruited into the study but withdraw from the study after randomization.
  • Do not attend both follow-up appointments.

Treatment and study plan

HIFU treatment

Device

HIFU for the management of cervical HR-HPV-related LSIL

Primary outcomes

  1. Efficacy of HIFU in reducing cervical HR-HPV related LSIL

    Time frame: 12 months

    • To determine the efficacy of HIFU in reducing cervical HR-HPV-related LSIL as evident by the reduction in the number of persistent cervical smear cytological abnormality when compared to observation as a standard management according to HKCOG Guidelines.

Secondary outcomes

  1. efficacy of HIFU in clearing cervical HR-HPV

    Time frame: 12 months

    The efficacy of HIFU in clearing cervical HR-HPV-related HPV will be compared to observation. Both HIFU and Observation group will have HPV testing at 6 and 12 months after recruitment, and the incidence of HR-HPV in both groups will be analyzed.

  2. Efficacy of HIFU in reducing the need for repeat colposcopy

    Time frame: 12 months

    The number of participants that required repeat colposcopy for persistent abnormal cervical smear in HIFU and Observation group will be compared.

  3. Safety and side effects of HIFU in the treatment of cervical LSIL

    Time frame: 6 months

    The treatment time, intraoperative blood loss, intraoperative pain level using visual analog scale (VAS) pain score, and other discomfort are recorded. Patients will be called in 1 week for any postoperative side effects or complications such as discharge, bleeding, pain (including the VAS pain score) or discomfort, for which, additional telephone or clinic follow-up will be arranged if necessary. The visual analog scale pain score will range from a minimum value of 0 to a maximum value of 10, with higher scores mean worse pain level.

  4. Patient satisfaction in using HIFU in the treatment of cervical LSIL

    Time frame: 1 months

    The level of patient satisfaction in using HIFU in the treatment of cervical LSIL level will be evaluated using visual analog scale (VAS) score, immediately after, and 1 month after HIFU treatment. The visual analog scale patient satisfaction score will range from a minimum value of 0 to a maximum value of 5, with higher scores mean higher satisfaction.

Study contacts

Contact information is provided by the study sponsor or research team.

Vincent YT Dr. Cheung, MBBS, MRCOG, FHKAM, FRCOG

CONTACT

[email protected]

+85222554265

Sponsors and collaborators

Lead sponsor

Queen Mary Hospital, Hong Kong

Other

Registry information

Official study title

High-Intensity Focused Ultrasound (HIFU) Versus Observation for Low-Grade Squamous Intraepithelial Lesions of Cervix: A Randomized Controlled Trial

Acronym: HIFU Colpo

Important dates

Study start
2026
Primary completion
2028
Study completion
2028
First posted
Mar 10, 2026
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.